GlassScriptPhysician profile
Faizan Babar
NPI 1477966935
$5,127.95
in general payments reported to CMS, 2019-2025
27 companies · $829 in 2025
The $829 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $350 · 2020: $345 · 2021: $552 · 2022: $1,130 · 2023: $837 · 2024: $1,085 · 2025: $829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,693 · Education: $58.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,692.79 |
| Education | $58.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $911.03 | 2019-2025 | Lokelma, Farxiga |
| Vifor Pharma, INC. | $459.13 | 2020-2025 | Veltassa, Korsuva |
| Fresenius USA Marketing, INC. | $437.04 | 2020-2025 | Velphoro, Velphoro, Korsuva |
| Amgen INC. | $429.34 | 2020-2025 | Krystexxa, Tavneos, Aranesp |
| Otsuka America Pharmaceutical, INC. | $339.23 | 2019-2025 | Jynarque |
| Travere Therapeutics, INC. | $294.03 | 2022-2025 | |
| Horizon Therapeutics Plc | $283.38 | 2021-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $283.14 | 2020-2025 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $266.98 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $208.23 | 2022-2025 | Lupkynis |
| Opko Pharmaceuticals, LLC | $200.77 | 2019-2025 | Rayaldee |
| Calliditas Therapeutics US INC. | $197.06 | 2022-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $172.24 | 2021-2025 | Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.64 | 2024-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $88.54 | 2024-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $79.27 | 2021-2025 | Ultomiris |
| Daiichi Sankyo INC. | $67.23 | 2019-2023 | Injectafer |
| Xeris Pharmaceuticals, INC. | $62.30 | 2021 | |
| Lilly USA, LLC | $52.27 | 2024 | Jardiance |
| Mallinckrodt Enterprises LLC | $38.03 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.10 | 2025 | Gattex |
| Akebia Therapeutics INC | $19.92 | 2021 | |
| Novo Nordisk INC | $19.39 | 2025 | |
| Ardelyx, INC. | $19.11 | 2024 | Ibsrela |
| Nxstage Medical, INC. | $19.03 | 2025 | Nxstage System One, Liberty Select Cycler |
| Genzyme Corporation | $14.21 | 2019 | |
| Shire North American Group INC | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faizan Babar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.